{"id":"warfarin-and-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding (major and minor)"},{"rate":"0.1-3%","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":"5-10%","effect":"Injection site reactions (enoxaparin)"},{"rate":"1-5%","effect":"Elevated liver enzymes"},{"rate":"<1%","effect":"Skin necrosis (warfarin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin works by antagonizing vitamin K, thereby reducing synthesis of clotting factors II, VII, IX, and X in the liver. Enoxaparin potentiates antithrombin III's inhibition of factors Xa and IIa, providing rapid anticoagulation. Together, they provide both immediate (enoxaparin) and sustained (warfarin) anticoagulation, often used during warfarin initiation to bridge therapy.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors while enoxaparin is a low-molecular-weight heparin that enhances antithrombin activity to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:06.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism (DVT/PE) prevention and treatment"},{"name":"Atrial fibrillation with stroke risk"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT03178864","phase":"PHASE2","title":"Study of Rivaroxaban for CeREbral Venous Thrombosis","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2019-03-12","conditions":"Cerebral Venous Thrombosis","enrollment":55},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-19","conditions":"Thrombosis","enrollment":192},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100},{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168},{"nctId":"NCT05300555","phase":"PHASE4","title":"Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2021-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":50},{"nctId":"NCT03465735","phase":"NA","title":"Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2017-01-13","conditions":"Acute DVT of Lower Extremity","enrollment":15},{"nctId":"NCT04235569","phase":"PHASE4","title":"Warfarin Initiation in Mechanical Mitral Valve Replacement Patients","status":"COMPLETED","sponsor":"Sarah Sabry Hashem","startDate":"2018-03-01","conditions":"Mitral Valve Disease","enrollment":50},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT03490994","phase":"PHASE4","title":"Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-04-10","conditions":"Acute Heart Failure","enrollment":150},{"nctId":"NCT03747081","phase":"PHASE1, PHASE2","title":"Efficacy Comparison of Warfarin Versus Rivaroxaban CVT","status":"UNKNOWN","sponsor":"Isfahan University of Medical Sciences","startDate":"2018-09-01","conditions":"Cerebral Venous Thrombosis","enrollment":50},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT00790335","phase":"PHASE3","title":"Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-11","conditions":"Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome","enrollment":692},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100},{"nctId":"NCT02743052","phase":"","title":"Anticoagulation in Cancer Related Stroke","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-10","conditions":"Cancer, Stroke","enrollment":400},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT01880216","phase":"PHASE3","title":"Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT","status":"COMPLETED","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2013-06","conditions":"Deep Vein Thrombosis","enrollment":312},{"nctId":"NCT00238667","phase":"PHASE3","title":"To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2005-11","conditions":"Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection","enrollment":250},{"nctId":"NCT02375646","phase":"NA","title":"Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-05","conditions":"Post Polypectomy Bleeding in Anticoagulated Patients, Gastrointestinal Hemorrhage","enrollment":286},{"nctId":"NCT01747746","phase":"PHASE4","title":"Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2012-10","conditions":"Atrial Fibrillation, Stroke, Thrombo-embolism","enrollment":33},{"nctId":"NCT01986192","phase":"NA","title":"Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2013-11","conditions":"Ileofemoral Deep Vein Thrombosis","enrollment":72},{"nctId":"NCT02240927","phase":"NA","title":"Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves","status":"UNKNOWN","sponsor":"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","startDate":"2010-01","conditions":"Pregnancy, Heart; Complications, Valve, Prosthesis","enrollment":40},{"nctId":"NCT02159287","phase":"PHASE2","title":"Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke","status":"UNKNOWN","sponsor":"Shiraz University of Medical Sciences","startDate":"2014-01","conditions":"Embolic Stroke","enrollment":80},{"nctId":"NCT00643201","phase":"PHASE3","title":"Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Venous Thrombosis","enrollment":5614},{"nctId":"NCT00097357","phase":"PHASE2, PHASE3","title":"BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-10","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":1238},{"nctId":"NCT00253396","phase":"PHASE4","title":"Patients Preference With Self-Injection: The PRISM Study","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2005-10","conditions":"Bruises","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":721,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coumadin"],"phase":"marketed","status":"active","brandName":"Warfarin and Enoxaparin","genericName":"Warfarin and Enoxaparin","companyName":"Cook County Health","companyId":"cook-county-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors while enoxaparin is a low-molecular-weight heparin that enhances antithrombin activity to prevent blood clot formation. Used for Venous thromboembolism (DVT/PE) prevention and treatment, Atrial fibrillation with stroke risk, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}